Trial NCT01343823

View at ClinicalTrials.gov 
Org. Study IDs: DX-88/27

Last trial update was posted on 2021-06-11

MeSH Interventions

Ecallantide

MeSH Conditions

Angioedema

Other Conditions

ACE Inhibitor Induced Angioedema

Stopping Reasons

Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.

Limitations And Caveats

The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID